We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.64 | 0.17% | 958.64 | 946.57 | 960.00 | 962.10 | 950.27 | 958.00 | 352,001 | 21:21:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
Sanofi |
2. Issuer Name
and
Ticker or Trading Symbol
REGENERON PHARMACEUTICALS INC [ REGN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
54 RUE LA BOETIE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
PARIS, I0 75008 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 1/11/2017 | P | 1592 (1) (2) | A | $362.4664 (1) (3) | 23419988 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 6546 (1) (2) | A | $363.3534 (1) (5) | 23426534 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 13226 (1) (2) | A | $364.3224 (1) (6) | 23439760 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 19858 (1) (2) | A | $365.2018 (1) (7) | 23459618 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 3979 (1) (2) | A | $366.0528 (1) (8) | 23463597 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 1986 (1) (2) | A | $367.2911 (1) (9) | 23465583 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 2336 (1) (2) | A | $368.3472 (1) (10) | 23467919 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 2517 (1) (2) | A | $369.3 (1) (11) | 23470436 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 900 (1) (2) | A | $370.1789 (1) (12) | 23471336 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 1259 (1) (2) | A | $371.5346 (1) (13) | 23472595 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 2675 (1) (2) | A | $372.8741 (1) (14) | 23475270 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 2784 (1) (2) | A | $373.9018 (1) (15) | 23478054 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 3830 (1) (2) | A | $374.5922 (1) (16) | 23481884 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 3016 (1) (2) | A | $375.8789 (1) (17) | 23484900 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 3851 (1) (2) | A | $376.7488 (1) (18) | 23488751 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 5313 (1) (2) | A | $377.8368 (1) (19) | 23494064 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 9520 (1) (2) | A | $378.7635 (1) (20) | 23503584 | I | See note (4) | ||
Common Stock | 1/11/2017 | P | 2110 (1) (2) | A | $379.5636 (1) (21) | 23505694 | I | See note (4) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Remarks:
Exhibit 24 - Power of Attorney (incorporated herein by reference to Exhibit 24 to Form 4 filed by the Reporting Person with the SEC on February 3, 2016, with respect to Alnylam Pharmaceuticals, Inc.). |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Sanofi
54 RUE LA BOETIE PARIS, I0 75008 |
|
X |
|
|
Signatures
|
||
/s/ Alexandra Roger, attorney-in-fact | 1/13/2017 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions